Citadel advises the founders of India's most consequential life-science companies, and invests alongside them. Fifteen years. $1 billion advised. One standard.
"Investor by mind.
Entrepreneur by heart."
Founded in March 2009, Citadel is a boutique investment bank focused exclusively on life sciences. We work for founders who build to last, advising on the transactions that define their next decade, and investing our own capital where we see the same conviction we ask of our clients.
Headquartered in Hyderabad with a presence in Singapore, we sit at the centre of a network of industry specialists, family offices, financial sponsors and strategic investors across India, Europe, the Middle East and the United States.
We are among the few mid-market advisory firms in India with a proprietary investment arm, which means the judgement we bring to a mandate is the same judgement we apply to our own balance sheet.
Buy-side and sell-side, domestic and cross-border. From Rising Pharma's US platform to Celon's strategic exit, processes run for value and certainty.
Early, growth and pre-IPO. Minority and majority. Capital placed from Sequoia, Rabo, Tata Capital, EBRD, CDC, DPI and global healthcare leaders.
We conceive platforms, not just advise them. Viyash with Carlyle ($300m) was jointly conceptualised with the sponsor.
Bespoke structures that protect founder legacy while unlocking growth capital. No template, every family, every chapter.
Bridge rounds and creative structures for high-growth, high-risk stages where conventional capital won't stretch.
When the unsolicited call comes, calm, leverage, and long-term holder value. The quiet work that matters most.
A record of mandates where Citadel served as exclusive financial advisor. The proof no competitor can fabricate.
A curated selection. Additional confidential mandates omitted. Values as disclosed / advised.
Angel, pre-Series A and bridge, early, high-risk stages where our network and domain expertise matter most.
Monoclonal antibody biosimilars, 4 mAbs, a US$25bn market, Phase 3 ready. Co-promoted with a 76% stake. Exited via strategic sale to Sri Krishna Pharma.
Hybrid seeds across cotton, maize, fruits and vegetables. Market leader in cotton; NATCO Pharma holds a minority stake.
Clinical derma and cosmetology. 90% owned with two pharma veterans. Eight thousand dermatologists, a ₹9,000cr market.
India's first holistic EV platform, a full-stack transition to electric as adoption accelerates.
Oral thin films, differentiated technology across pharmaceuticals and nutraceuticals.
A tech-led QSR brand in India's rapidly growing food services and delivery market.
A knowledge resource for doctors, digital sales enablement and analytics for smarter pharma marketing.
Over 20 years advising large and mid-cap life-science companies on fundraises, strategic sales, acquisitions and divestitures. Previously Senior Relationship Manager, Goldman Sachs Asset Management, North America, after GE Financial Analytics. American CPA; Bachelors in Finance & Accounting, Osmania University.
With Citadel since March 2011. Leads business development, deal origination and diligence. Previously senior team leader at Capgemini. Electronics & Communication Engineer, JNTU Hyderabad; Member, Actuarial Society of India, Mumbai.
Joined October 2021. A decade in core pharma at Glenmark, evaluating acquisitions, executing divestments across geographies, raising growth capital. Leads deal origination and management. B.Pharm + MBA (NMIMS Mumbai), CFA Level 1.
For founders: a confidential, partner-led first conversation. If we cannot add meaningful value, we will tell you in that first meeting.
We work across India, Europe, the Middle East and the United States through a network of industry specialists, family offices and financial sponsors.
To begin, write to us with a short note on your company and the outcome you are working toward. Every enquiry is read by a partner.